Methylation inhibitor therapy in the treatment of myelodysplastic syndrome

Nature Clinical Practice Oncology

Volumn 2, Issue SUPPL. 1, 2005, Pages

  Silverman, Lewis R ^a   Mufti, Ghulam J ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Azacitidine; Clinical trials; Decitabine; Hypomethylation; Myelodysplastic syndrome

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BONE MARROW; BONE MARROW HYPOPLASIA; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; CYTOPENIA; DISEASE EXACERBATION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FOOD AND DRUG ADMINISTRATION; GRANULOCYTOPENIA; HUMAN; LEUKOPENIA; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; TRISOMY 8;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA MODIFICATION METHYLASES; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HUMANS; MYELODYSPLASTIC SYNDROMES; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 31344450167     PISSN: 17434254     EISSN: 17434262     Source Type: Journal    
DOI: 10.1038/ncponc0347     Document Type: Review

References (45)

1. Gore S (2004) Classification, treatment goals, and management principles for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 3-6
2. Bennett JM et al. (1976) Proposals for the classification of the acute leukaemias: French-American-British (FAB) cooperative group. Br J Haematol 33: 451-458
3. Bennett JM et al. (1982) Proposals for the classifications of myelodysplastic syndromes. Br J Haematol 51: 189-199
4. Bennett JM et al. (1985) Proposed revised criteria for the classification of acute myeloid leukemia: A report of the French-American-British Cooperative Group. Ann Intern Med 103: 620-625
5. Bennett JM (2000) World Health Organization classficiation of the acute leukemias and myelodysplastic syndrome. Int J Hematol 72: 131-133
6. Greenberg et al. (1997) International scoring system for evaluating prognosis in myelodysplastic syndrome. Blood 89: 2079-2088
7. Stone R (2004) Treatment options for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 7-10
8. List A (2004) Methyltransferase inhibitors: Changing the treatment algorithm for myelodysplastic syndromes. Cancer Control 11 (Suppl 6): 16-19
9. Herman JG and Baylin SB (2003) Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054
10. Anon (online 1 September 05) Press release: Approvable letter received from the FDA for Dacogen™ [http://investors.mgipharma.com/ phoenix.zhtml?c=73842&p=irol-newsArticle&ID= 751908&highlight=] (accessed 12 September 2005)
11. Kaminskas E et al. (2005) FDA drug approval summary: Azacidine (azacitidine™) for injectable suspension. Oncologist 10: 176-182
12. Kaminskas E et al. (2005) Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11: 3604-3608
13. Anon (online 19 May 05) Vidaza label and approval history [http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm?fuseaction=Search.Search_Drug_Name] (accessed 28 September 05)
14. Silverman LR et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B. J Clin Oncol 20: 2429-2440
15. Rüter B et al. (2005) Re-treatment results in second remission of MDS with previous response to low-dose 5-aza-2′-doxycytidine (Decitabine). Leuk Res 29 (Suppl 1): S65
16. 2/course) in myelodysplastic syndrome (MDS). Comparison of 3 different dose schedules [abstract]. J Clin Oncol 23: 6545
17. Wijermans P et al. (2000) Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: A multicenter phase II study in elderly patients. J Clin Oncol 18: 956-962
18. Garcia-Manero G et al. (2005) Results of a phase I/II study of the combination of 5-aza-2′-deoxycitidine and valproic acid in patients with acute myeloid leukemia and myelodysplastic syndrome [abstract]. J Clin Oncol 23: 6544.
19. Saba HI et al. (2005) Clinical benefit and survival endpoints from a phase III trial comparing decitabine (DAC) vs. supportive care (SC) in patients with advanced myelodysplastic syndromes (MDS) [abstract]. J Clin Oncol 23: 6543
20. Burchenal JH and Carter SK (1972) New cancer chemotherapeutic agents. Cancer 30: 1639-1646
21. Massimo L and Comelli A (1975) New drugs for the therapy of acute leukemia. Minerva Med 66: 2568-2576
22. Silverman LR et al. (1993) Effects of treatment with azacitidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (Suppl 1): 21-29
23. Silverman LR (2001) Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS). Oncologist 6 (Suppl 5): 8-14
24. Marcucci G et al. (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45: 597-603
25. Kornblith AB et al. (2002) Impact of azacitidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: A Cancer and Leukemia Group B study. J Clin Oncol 20: 2441-2452
26. Najfeld V et al. (2004) The modulating effect of azacitidine (Aza C) on the cytogenetically tracked MDS clone impact survival [abstract]. Blood 104: 1429
27. Kantarjian HM et al. (1997) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11 (Suppl 1): S35-S36
28. Kantarjian HM et al. (2003) Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 98: 522-528
29. Pinto A and Zagonel V (1993) 5-Aza-2′-deoxycytidine (decitabine) and azacitidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: Past, present and future trends. Leukemia 7 (Suppl 1): 51-60
30. Issa JP et al. (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103: 1635-1640
31. Saiki JH et al. (1978) 5-Azacitidine in acute leukemia. Cancer 42: 2111-2114
32. Jones PA and Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20: 85-93
33. Issa JP (2003) Decitabine. Curr Opin Oncol 15: 446-451
34. Aparicio A and Weber JS (2002) Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr Opin Investig Drugs 3: 627-633
35. Goffin J and Eisenhauer E (2002) DNA methyltransferase inhibitors - state of the art. Ann Oncol 13: 1699-1716
36. National Comprehensive Cancer Network (online 21 September 04) Myelodysplastic syndromes Version 1.2005 [http://www.nccn.org/professionals/physician_gls/PDF/mds.pdf] (accessed 7 September 2005)
37. Cheson ED et al. (2000) Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96: 3671-3674
38. Cutler CS et al. (2004) A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 104: 579-585
39. Williamson PJ et al. (1994) Establishing the incidence of myelodysplastic syndrome. Br J Haematol 87: 743-745
40. Ho AY et al. (2004) Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning. Blood 104: 1616-1623
41. US Census Bureau (online 18 March 04) U.S. interim projections by age, sex, race, and Hispanic origin [http://www.census.gov/ipc/www/usinterimproj/natprojtab02a.pdf] and [http://www.census.gov/ipc/www/usinterimproj/natprojtab02b.pdf] (accessed 7 September 2005)
42. Christman JK (2002) azacitidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21: 5483-5495
43. Toyota M et al. (2001) Methylation profiling in acute myeloid leukemia. Blood 97: 2823-2829
44. Garcia-Manero G et al. (2002) DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 8: 2217-2224
45. Rudek MA et al. (2005) Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 23: 3906-3911